News Announcement

Panacea Biotec: Patent Dispute Settlement Agreement Between Panacea Biotec, Apotex And Celgene Corporation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Panacea Biotec Ltd. along with its partner, Apotex Inc. and Apotex Corp. (Apotex) have entered into a Settlement Agreement dated June 13, 2018, with Celgene Corporation, a global biopharmaceutical company headquartered in USA and its subsidiary Abraxis BioScience, LLC, for settlement of disputes regarding patents covering Abraxane? drug product and the Companys Abbreviated New Drug Application (ANDA) for paclitaxel protein bound particles for injectable suspension, 100mg/vial, a generic version of Abraxane?.

This is for your information and record please. Kindly acknowledge the receipt.

Ask Value Research aks value research information

No question is too small. Share your queries on personal finance, mutual funds, or stocks and let us simplify things for you.


Mutual Fund Insight turns 24! 🎉 Get 2 FREE anniversary guides: The Right SIP + The Big Funds